USP13 amplification in human HGSOC may contribute to the development of resistance of PI3K/AKT inhibitors in ovarian cancer, and targeting USP13 may overcome cancer cell resistance against targeted therapy for PI3K/AKT/mTOR pathway. Here, PIK3CA is linked to ovarian cancer.